HC Wainwright Lowers Valneva (NASDAQ:VALN) Price Target to $18.00

Valneva (NASDAQ:VALN) had its price target lowered by investment analysts at HC Wainwright from $19.00 to $18.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 288.77% from the stock’s previous close.

Valneva Stock Performance

Shares of VALN stock opened at $4.63 on Thursday. The stock has a market capitalization of $376.24 million, a PE ratio of -35.62 and a beta of 1.93. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The stock’s 50-day moving average price is $4.29 and its 200 day moving average price is $5.80. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC grew its holdings in shares of Valneva SE (NASDAQ:VALN) by 33.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.